Publications
US FDA letting FTC Decide if Orange Book Listings ‘Improper’
Quoted, BioWorld
Chad Landmon, Hatch-Waxman & Biologics Chair, offers insight on Orange Book listings.
Firm Highlights
Slide 1 of 5
- PublicationCMS, FDA Propose RAPID Pathway for Medicare Coverage of Certain Medical DevicesThe proposed RAPID pathway would create a new voluntary CMS/FDA process for certain innovative medical devices, with the stated goals of expediting Medicare coverage, improving efficiency and supporting patient access.Read more
- EventAI Risk Management: Navigating Cybersecurity and Privacy ComplianceAs part of our Digital Risk and Innovation Summit Series, join Polsinelli for this webinar that will explore the key cybersecurity and privacy issues associated with AI.Read more
- NewsPolsinelli Bolsters Public Policy Practice with Senior Policy Advisor Eli GreenspanPolsinelli is pleased to announce that Eli Greenspan has joined the firm as a senior policy advisor in its Public Policy Practice in Washington, D.C.Read more
- PublicationRise in IP Litigation Brings Patent vs. Trade Secret Strategy Back Into FocusPatent and trade secret protection solve different IP strategy problems, with patents generally fitting inventions likely to be disclosed and trade secrets generally fitting information that can remain confidential.Read more
- NewsPolsinelli Earns Firm and Attorney Recognitions in 2026 IP STARSPolsinelli is pleased to announce that the firm and 13 attorneys from its Intellectual Property Practice have been recognized in the 2026 edition of IP STARS, published by Managing IP.Read more